enVVeno Medical
NVNO
21 hedge funds and large institutions have $8.11M invested in enVVeno Medical in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
81,600% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $2K
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.03% more ownership
Funds ownership: 0.62% → 0.65% (+0.03%)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
38% less capital invested
Capital invested by funds: $13M → $8.11M (-$4.87M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$524K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$252K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.5K |
| 4 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$47.9K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$47.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$319K |
| 2 |
Two Sigma Investments
New York
|
-$213K |
| 3 |
Two Sigma Advisers
New York
|
-$55.9K |
| 4 |
Morgan Stanley
New York
|
-$34K |
| 5 |
BlackRock
New York
|
-$22.2K |
NVNO Hedge Fund Activity: Q2 2022 in Review
21 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q2 2022, worth a combined $8.11M — down 38% from $13M a quarter earlier.
Fund positioning in NVNO was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 5 trimmed.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $524K. The largest seller was Kepos Capital, exiting entirely with an estimated $319K sold.
- 21 institutional investors held enVVeno Medical (NVNO) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $8.11M of enVVeno Medical stock for Q2 2022, down 38% quarter-over-quarter.
- 3 funds opened new enVVeno Medical positions in Q2 2022 and 3 closed out, a net change of 0 holders.
- The largest enVVeno Medical buyer in Q2 2022 was UBS O'Connor, an estimated $524K added.
- The largest enVVeno Medical seller in Q2 2022 was Kepos Capital, an estimated $319K sold.
Based on aggregated 13F filings for Q2 2022.